levodopa/carbidopa CR / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 13 Diseases   1 Trial   1 Trial   39 News 
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Trial completion date, Trial primary completion date:  Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease (clinicaltrials.gov) -  Aug 24, 2022   
    P4,  N=42, Recruiting, 
    The AUC for levodopa/carbidopa multiparticulate matrix (Formulation 3: 484.98 Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Feb 2022 --> Dec 2022
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Enrollment open:  TESDR: Treating Early Stage Diabetic Retinopathy (clinicaltrials.gov) -  Jul 18, 2022   
    P1,  N=244, Enrolling by invitation, 
    They differ in their profile of effects and have been tested only for specific patient groups. Not yet recruiting --> Enrolling by invitation
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Trial initiation date:  TESDR: Treating Early Stage Diabetic Retinopathy (clinicaltrials.gov) -  Apr 8, 2022   
    P1,  N=244, Not yet recruiting, 
    Not yet recruiting --> Enrolling by invitation Initiation date: Apr 2022 --> Jul 2022
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    New P1 trial:  TESDR: Treating Early Stage Diabetic Retinopathy (clinicaltrials.gov) -  Nov 23, 2021   
    P1,  N=244, Not yet recruiting, 
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Trial completion date, Trial primary completion date:  Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease (clinicaltrials.gov) -  Aug 31, 2021   
    P4,  N=42, Recruiting, 
    This may widen access to LCIG for PD patients who may not be suitable or unable to tolerate PEG-J. Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Jul 2021 --> Feb 2022
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Trial completion date, Trial primary completion date:  Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease (clinicaltrials.gov) -  Aug 8, 2020   
    P4,  N=42, Recruiting, 
    2020; 81:XXX-XXX Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Jan 2021 --> Jul 2021
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  The Effect of Dopamine on Diabetic Retinopathy (clinicaltrials.gov) -  Oct 9, 2019   
    P1,  N=60, Completed, 
    Trial completion date: Sep 2021 --> Dec 2021 | Trial primary completion date: Jan 2021 --> Jul 2021 Enrolling by invitation --> Completed | N=45 --> 60 | Trial completion date: Dec 2019 --> Aug 2019 | Trial primary completion date: Dec 2019 --> Aug 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  The Effect of Dopamine on Diabetic Retinopathy (clinicaltrials.gov) -  Jan 23, 2019   
    P1,  N=45, Enrolling by invitation, 
    However, based on this preliminary data, we propose that this promising technique warrants further investigation as it has the potential to reduce procedure related complications and may also allow access to LCIG therapy for patients in which PEG-J is unsuitable or not tolerated. Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease (clinicaltrials.gov) -  Sep 11, 2018   
    P4,  N=42, Recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Apr 2020 --> Sep 2021 | Initiation date: Dec 2016 --> May 2017 | Trial primary completion date: Apr 2020 --> Jan 2021
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Trial primary completion date:  The Effect of Dopamine on Diabetic Retinopathy (clinicaltrials.gov) -  Jan 8, 2018   
    P1,  N=45, Enrolling by invitation, 
    Trial completion date: Apr 2020 --> Sep 2021 | Initiation date: Dec 2016 --> May 2017 | Trial primary completion date: Apr 2020 --> Jan 2021 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Trial primary completion date:  The Effect of Dopamine on Diabetic Retinopathy (clinicaltrials.gov) -  Feb 1, 2017   
    P1,  N=45, Enrolling by invitation, 
    Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Enrollment status:  The Effect of Dopamine on Diabetic Retinopathy (clinicaltrials.gov) -  Oct 11, 2016   
    P1,  N=45, Enrolling by invitation, 
    Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Enrolling by invitation
  • ||||||||||  levodopa/carbidopa CR / Generic mfg.
    Trial primary completion date:  The Effect of Dopamine on Diabetic Retinopathy (clinicaltrials.gov) -  Aug 12, 2016   
    P1,  N=45, Recruiting, 
    Recruiting --> Enrolling by invitation Trial primary completion date: Jul 2016 --> Dec 2016